81 related articles for article (PubMed ID: 21122350)
1. [Effect of ZD6474 on the proliferation of imatinib-resistant K562 cells].
Jia HY; Wu XM; Wang ZY; Deng XY; Lin Z; Feng GL; Huang WL
Zhonghua Xue Ye Xue Za Zhi; 2010 Jun; 31(6):371-5. PubMed ID: 21122350
[TBL] [Abstract][Full Text] [Related]
2. ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells.
Jia HY; Wu JX; Zhu XF; Chen JM; Yang SP; Yan HJ; Tan L; Zeng YX; Huang W
Leuk Res; 2009 Nov; 33(11):1512-9. PubMed ID: 19394692
[TBL] [Abstract][Full Text] [Related]
3. [The role of Src kinase inhibitor ZD6474 on multi-drug resistant K562/A02 cells].
Jia HY; Li J; Wang ZY; Zhou Q; Wu XM
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):220-4. PubMed ID: 22781612
[TBL] [Abstract][Full Text] [Related]
4. [Effect of phenylhexyl isothiocyanate on drug-resistance to imatinib in K562/G01 cell line].
Wu RJ; Huang YQ; Ma XD
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):149-52. PubMed ID: 23611223
[TBL] [Abstract][Full Text] [Related]
5. [Suppression of NAMPT expression enhances the sensitivity of K562 cells to imatinib and its relative mechanism].
Lin PP; Bai XJ; Yue ZX; Yan SF; Li ZW; Gao C; Mei YY; Wang KL; Li WJ; Ding W; Li ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):235-41. PubMed ID: 22541073
[TBL] [Abstract][Full Text] [Related]
6. [Anti-Leukemia Effect and Mechanism of Oridonin on Imatinib-Sensitive and Imatinib-Resistant K562 Cells].
Shan QQ; Guo Y; Gong YP; Lin J; Wang YS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1378-1383. PubMed ID: 29070111
[TBL] [Abstract][Full Text] [Related]
7. [Apoptosis-inducing effect of tetrandrine and imatinib on K562/G01 cells and its related mechanism].
Shi DX; Ma LM; Lu YJ; Bai B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):723-8. PubMed ID: 24989284
[TBL] [Abstract][Full Text] [Related]
8. [Effects of HO-1 gene expression on proliferation of imatinib resistant CML cells].
Wang JS; Chai BS; Fang Q; He YY; Chen C; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):388-91. PubMed ID: 21781496
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
10. [Effects of STI571 combined with As₂O₃ on proliferation, apoptosis and caspase 3, Bcl-xL expression of K562 cells].
Chen NY; Wang J; Wang XM; Zhang HX; Yan ZY; Wang YM; Zhang S; Yan B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):882-6. PubMed ID: 20723293
[TBL] [Abstract][Full Text] [Related]
11. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
12. [Triptolide inhibits proliferation and induces apoptosis of imatinib resistant K562/G01 cells].
Wen SQ; Ma LM; Lu YJ; Bai B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1148-52. PubMed ID: 24156423
[TBL] [Abstract][Full Text] [Related]
13. Guggulsterone of Commiphora mukul resin reverses drug resistance in imatinib-resistant leukemic cells by inhibiting cyclooxygenase-2 and P-glycoprotein.
Xu HB; Xu LZ; Mao XP; Fu J
Phytomedicine; 2014 Jun; 21(7):1004-9. PubMed ID: 24680616
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Kirschner KM; Baltensperger K
Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869
[TBL] [Abstract][Full Text] [Related]
15. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of an imatinib resistant cell line K562/G01 and its characterization].
Qi J; Peng H; Gu ZL; Liang ZQ; Yang CZ
Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):337-41. PubMed ID: 15308010
[TBL] [Abstract][Full Text] [Related]
17. [Cytotoxic activities of Celecoxib on leukemic cells and the synergistic effects of Celecoxib with Imatinib thereupon].
Li RJ; Gong FJ; Zhang GS
Zhonghua Yi Xue Za Zhi; 2006 May; 86(20):1417-20. PubMed ID: 16796927
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
19. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
